CureDuchenne Webinar with Dyne Therapeutics | FORZETTO Explained: Understanding the Phase 3 Trial of Zeleciment Rostudirsen (DYNE-251) for Duchenne
Date & Time: Aug 19, 2026 10:00 AM in
Description:Dyne Therapeutics presents design of ongoing FORZETTO study on z-rostudirsen (also known as DYNE-251) for individuals living with DMD amenable to exon 51 skipping
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.